Bioxytran, Inc. Receives Clearance of its Investigational New Drug Application from U.S. Food and Drug Administration to Initiate Clinical Trials of ProLectin-M

Bioxytran, Inc. announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA), to initiate clinical trials of ProLectin-M for the treatment of mild to moderate COVID-19 in standard risk patients.